Forbion, a leading European life sciences venture capital firm, announces a $2.3m seed investment in newly formed CoviCept Therapeutics, Inc., a California-based company that is developing a small molecule that inhibits the replication of SARS-CoV-2 and other RNA viruses.
January 19, 2021
· 4 min read